Evidence map›Paper›PMID 31485437›Full record

ArticleProstate international2019

Mike Allan Mortensen, Mads Hvid Poulsen, Oke Gerke, Jørn Skibsted Jakobsen, Poul Flemming Høilund-Carlsen, Lars Lund

Open access · goldAbstract read
In one paragraph

Article in Prostate international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Detection of recurrence sites usingProstate international · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mike Allan MortensenDepartment of Urology, Odense University Hospital, Odense, Denmark.
Mads Hvid PoulsenDepartment of Urology, Odense University Hospital, Odense, Denmark.
Oke GerkeDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Jørn Skibsted JakobsenDepartment of Urology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.
Poul Flemming Høilund-CarlsenDepartment of Nuclear Medicine, Odense University Hospital, Odense, Denmark.
Lars LundDepartment of Urology, Odense University Hospital, Odense, Denmark.
Odense University Hospital · DKGentofte Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of molecular imaging in staging of prostate cancer (PC) is debated. In patients with newly diagnosed PC we investigated the diagnostic value of MATERIALS AND

methodsBetween January 2013 and April 2016, 143 patients, aged 49-83, mean 69, years with newly diagnosed PC and disease characteristics necessitating WBS underwent both WBS and

resultsBone metastases were detected in 8/143 patients and sensitivity and specificity of WBS were 37.5% and 85.2% versus 100.0% and 96.3% with

conclusionsFindings in this study suggested that

Indexed as

CholineDiagnostic imagingPositron emission tomographyProstatic neoplasms

Identifiers

PMID31485437
PMCPMC6713799
OpenAlexW2908799495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.